litlas
ログインアカウント作成

Melissa L. Johnson

2010–2026 年に発表

179
論文数
23,534
被引用数
65
h 指数
158
i10 指数

被引用数

Melissa L. Johnson の年別被引用数1997 年: 被引用 1 件2000 年: 被引用 3 件2001 年: 被引用 1 件2003 年: 被引用 1 件2010 年: 被引用 2 件2011 年: 被引用 4 件2012 年: 被引用 13 件2013 年: 被引用 37 件2014 年: 被引用 44 件2015 年: 被引用 36 件2016 年: 被引用 52 件2017 年: 被引用 48 件2018 年: 被引用 127 件2019 年: 被引用 609 件2020 年: 被引用 927 件2021 年: 被引用 1,284 件2022 年: 被引用 1,337 件2023 年: 被引用 1,288 件2024 年: 被引用 2,463 件2025 年: 被引用 1,719 件2026 年: 被引用 43 件1998〜1999 年は被引用が無いため表示していません2002 年は被引用が無いため表示していません2004〜2009 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,278 件、この内訳の 25.1%中国: 引用元論文 1,850 件、この内訳の 14.1%イタリア: 引用元論文 756 件、この内訳の 5.8%イギリス: 引用元論文 625 件、この内訳の 4.8%フランス: 引用元論文 583 件、この内訳の 4.4%ドイツ: 引用元論文 576 件、この内訳の 4.4%日本: 引用元論文 558 件、この内訳の 4.3%スペイン: 引用元論文 531 件、この内訳の 4.1%オーストラリア: 引用元論文 335 件、この内訳の 2.6%カナダ: 引用元論文 335 件、この内訳の 2.6%スイス: 引用元論文 328 件、この内訳の 2.5%韓国: 引用元論文 326 件、この内訳の 2.5%
0%25.1%その他 22.8%

機関

分野

  • Medicine73.3%
  • Biochemistry, Genetics and Molecular Biology18.8%
  • Immunology and Microbiology5.2%
  • Engineering0.5%
  • Chemistry0.5%
  • Computer Science0.4%
  • その他1.3%

トピック

  • Lung Cancer Treatments and Mutations9.7%
  • Cancer Immunotherapy and Biomarkers9.6%
  • Lung Cancer Research Studies8.7%
  • CAR-T cell therapy research3.6%
  • Cancer Genomics and Diagnostics3.3%
  • Immunotherapy and Immune Responses3%
  • その他62.1%

共著者

全論文

検索で開く
  1. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

    著者: Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna, Libor Havel, Maciej Krzakowski, Maximilian J. Hochmair, Florian Huemer, György Losonczy, Melissa L. Johnson, Makoto Nishio, Martin Reck, Tony Mok, Sivuonthanh Lam, David S. Shames, Juan Liu, Beiying Ding, Ariel López-Chávez, Fairooz F. Kabbinavar, Wei Lin, Alan Sandler, Stephen V. Liu - New England Journal of Medicine 2018 被引用: 3,507

  2. Acquired Resistance to KRAS G12C Inhibition in Cancer

    著者: Mark M. Awad, Shengwu Liu, Igor I. Rybkin, Kathryn C. Arbour, Julien Dilly, Viola W. Zhu, Melissa L. Johnson, Rebecca S. Heist, Tejas Patil, Gregory J. Riely, Joseph O. Jacobson, Xiaoping Yang, Nicole S. Persky, David E. Root, Kristen E. Lowder, Hanrong Feng, Shannon S. Zhang, Kevin M. Haigis, Yin P. Hung, Lynette M. Sholl, Brian M. Wolpin, Julie Wiese, Jason Christiansen, Jessica Lee, Alexa B. Schrock, Lee P. Lim, Kavita Garg, Mark Li, Lars D. Engstrom, Laura Waters, J. David Lawson, Peter Olson, Piro Lito, Sai-Hong I. Ou, James G. Christensen, Pasi A. Jänne, Andrew J. Aguirre - New England Journal of Medicine 2021 被引用: 1,164

  3. Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation

    著者: Pasi A. Jänne, Gregory J. Riely, Shirish M. Gadgeel, Rebecca S. Heist, Sai‐Hong Ignatius Ou, Jose M. Pacheco, Melissa L. Johnson, Joshua K. Sabari, Konstantinos Leventakos, Edwin Yau, Lyudmila Bazhenova, Marcelo V. Negrão, Nathan A. Pennell, Jun Zhang, Kenna Anderes, Hirak Der‐Torossian, Thian Kheoh, Karen Velastegui, Xiaohong Yan, James G. Christensen, Richard C. Chao, Alexander I. Spira - New England Journal of Medicine 2022 被引用: 984

  4. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

    著者: Adrianus J. de Langen, Melissa L. Johnson, Julien Mazières, Anne‐Marie C. Dingemans, Giannis Mountzios, Miklos Pless, Jürgen Wolf, Martin Schüler, H. Léna, Ferdinandos Skoulidis, Yasuto Yoneshima, Sang‐We Kim, Helena Linardou, Silvia Novello, Anthonie J. van der Wekken, Yuanbin Chen, Solange Peters, Enriqueta Felip, Benjamin Solomon, Suresh S. Ramalingam, Christophe Dooms, Colin R. Lindsay, Carlos Gil Ferreira, Normand Blais, Cynthia C. Obiozor, Yang Wang, Bhakti Mehta, Tracy Varrieur, Gataree Ngarmchamnanrith, Björn Stollenwerk, David Waterhouse, Luis Paz‐Ares - The Lancet 2023 被引用: 566

  5. The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

    著者: Jill Hallin, Lars D. Engstrom, Lauren Hargis, Andrew Calinisan, Ruth Aranda, David M. Briere, Niranjan Sudhakar, Vickie Bowcut, Brian R. Baer, Joshua A. Ballard, Michael Burkard, Jay B. Fell, John P. Fischer, Guy Vigers, Jenny Y. Xue, Sole Gatto, Julio Fernandez-Banet, Adam Pavlı́ček, Karen Velastagui, Richard C. Chao, Jeremy Barton, Mariaelena Pierobon, Elisa Baldelli, Emanuel F. Patricoin, Douglas P. Cassidy, Matthew A. Marx, Igor I. Rybkin, Melissa L. Johnson, Sai‐Hong Ignatius Ou, Piro Lito, Kyriakos P. Papadopoulos, Pasi A. Jänne, Peter Olson, James G. Christensen - Cancer Discovery 2019 被引用: 1,282

  6. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

    著者: Myung‐Ju Ahn, Byoung Chul Cho, Enriqueta Felip, Ippokratis Korantzis, Kadoaki Ohashi, Margarita Majem, Óscar Juan, Sabin Handzhiev, Hiroki Izumi, Jong Seok Lee, Rafał Dziadziuszko, Jürgen Wolf, Fiona Blackhall, Martin Reck, Jean Bustamante Alvarez, Horst-Dieter Hummel, Anne‐Marie C. Dingemans, Jacob Sands, Hiroaki Akamatsu, Taofeek K. Owonikoko, Suresh S. Ramalingam, Hossein Borghaei, Melissa L. Johnson, Shuang Huang, Sujoy Mukherjee, Mukul Minocha, Tony Jiang, Pablo Martínez, Erik S. Anderson, Luis Paz‐Ares - New England Journal of Medicine 2023 被引用: 482

  7. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

    著者: Byoung Chul Cho, Delvys Rodríguez‐Abreu, Maen Hussein, Manuel Cobo, A. Patel, Nevena Sečen, Ki Hyeong Lee, Bartomeu Massutí, Sandrine Hiret, James Chih Hsin Yang, Fabrice Barlési, Dae Ho Lee, Luis Paz Ares, Robert W. Hsieh, Namrata S. Patil, Patrick J. Twomey, Xiaoying Yang, Raymond D. Meng, Melissa L. Johnson - The Lancet Oncology 2022 被引用: 424

  8. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

    著者: Michael R. Migden, Danny Rischin, Chrysalyne D. Schmults, Alexander Guminski, Axel Hauschild, Karl D. Lewis, Christine H. Chung, Leonel F. Hernandez‐Aya, Annette M. Lim, Anne Lynn S. Chang, Guilherme Rabinowits, Alesha Thai, Lara Dunn, Brett Hughes, Nikhil I. Khushalani, Badri Modi, Dirk Schadendorf, Bo Gao, Frank Seebach, Siyu Li, Jingjin Li, Melissa Mathias, Jocelyn Booth, Kosalai Kal Mohan, Elizabeth Stankevich, Hani M. Babiker, Irene Braña, Marta Gil-Martín, Jade Homsi, Melissa L. Johnson, Víctor Moreno, Jiaxin Niu, Taofeek K. Owonikoko, Kyriakos P. Papadopoulos, George D. Yancopoulos, Israel Lowy, Matthew G. Fury - New England Journal of Medicine 2018 被引用: 1,393

  9. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study

    著者: Melissa L. Johnson, Byoung Chul Cho, Alexander Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, К. К. Лактионов, Sang‐We Kim, Grygorii Ursol, Maen Hussein, Farah Louise Lim, Cheng‐Ta Yang, Luiz H. Araujo, Haruhiro Saito, Niels Reinmuth, Xiaojin Shi, Lynne Poole, Solange Peters, Edward B. Garon, Tony Mok, for the POSEIDON investigators - Journal of Clinical Oncology 2022 被引用: 434

  10. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

    著者: Luis Paz‐Ares, Stéphane Champiat, W. Victoria Lai, Hiroki Izumi, Ramaswamy Govindan, Michael Boyer, Horst-Dieter Hummel, Hossein Borghaei, Melissa L. Johnson, Neeltje Steeghs, Fiona Blackhall, Afshin Dowlati, Noemı́ Reguart, Tatsuya Yoshida, Kai He, Shirish M. Gadgeel, Enriqueta Felip, Yiran Zhang, Amrita Pati, Mukul Minocha, Sujoy Mukherjee, Amanda Goldrick, Dirk Nagorsen, Nooshin Hashemi Sadraei, Taofeek K. Owonikoko - Journal of Clinical Oncology 2023 被引用: 294

  11. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

    著者: Helena A. Yu, Yasushi Goto, Hidetoshi Hayashi, Enriqueta Felip, James Chih‐Hsin Yang, Martin Reck, Kiyotaka Yoh, Se‐Hoon Lee, Luis Paz‐Ares, Benjamin Besse, Paolo Bironzo, Dong‐Wan Kim, Melissa L. Johnson, Yi‐Long Wu, Thomas John, Steven Kao, Toshiyuki Kozuki, Erminia Massarelli, Jyoti D. Patel, Egbert F. Smit, Karen L. Reckamp, Qian Dong, Pomy Shrestha, Pang‐Dian Fan, Parul Patel, Andrea Sporchia, David Sternberg, Dalila Sellami, Pasi A. Jänne - Journal of Clinical Oncology 2023 被引用: 225

  12. Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    著者: Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, Herbert H. Loong, Melissa L. Johnson, Justin F. Gainor, Caroline E. McCoach, Oliver Gautschi, Benjamin Besse, Byoung Chul Cho, Nir Peled, Jared Weiss, Yu-Jung Kim, Yuichiro Ohe, Makoto Nishio, Keunchil Park, Jyoti D. Patel, Takashi Seto, Tomohiro Sakamoto, Ezra Y. Rosen, Manisha H. Shah, Fabrice Barlési, Philippe A. Cassier, Lyudmila Bazhenova, Filippo de Braud, Elena Garralda, Vamsidhar Velcheti, Miyako Satouchi, Kadoaki Ohashi, Nathan A. Pennell, Karen L. Reckamp, Grace K. Dy, Jürgen Wolf, Benjamin Solomon, Gerald S. Falchook, Kevin Ebata, Michele Nguyen, Binoj C. Nair, Edward Y. Zhu, Luxi Yang, Xin Huang, Elizabeth Olek, S. Michael Rothenberg, Kōichi Goto, Vivek Subbiah - New England Journal of Medicine 2020 被引用: 836

  13. MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP -Deleted Cancer

    著者: Lars D. Engstrom, Ruth Aranda, Laura Waters, Krystal Moya, Vickie Bowcut, Laura Vegar, David Trinh, Allan Hebbert, Christopher R. Smith, Svitlana Kulyk, J. David Lawson, Leo He, Laura D. Hover, Julio Fernandez-Banet, Jill Hallin, Darin Vanderpool, David M. Briere, Alice Blaj, Matthew A. Marx, Jordi Rodón, Michael Offin, Kathryn C. Arbour, Melissa L. Johnson, David J. Kwiatkowski, Pasi A. Jänne, Candace L. Haddox, Kyriakos P. Papadopoulos, Jason T. Henry, Konstantinos Leventakos, James G. Christensen, Ronald Shazer, Peter Olson - Cancer Discovery 2023 被引用: 194

  14. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR -Mutated Non–Small Cell Lung Cancer

    著者: Pasi A. Jänne, Christina Baik, Wu-Chou Su, Melissa L. Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong-Wan Kim, Marianna Koczywas, Kathryn A. Gold, Conor E. Steuer, Haruyasu Murakami, James Chih-Hsin Yang, Sang-We Kim, Michele Vigliotti, Rong Shi, Zhenhao Qi, Yang Qiu, Lihui Zhao, David Sternberg, Channing Yu, Helena A. Yu - Cancer Discovery 2021 被引用: 287

  15. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)

    著者: Sai‐Hong Ignatius Ou, Pasi A. Jänne, Ticiana Leal, Igor I. Rybkin, Joshua K. Sabari, Minal Barve, Lyudmila Bazhenova, Melissa L. Johnson, Karen Velastegui, Cornelius Cilliers, James G. Christensen, Xiaohong Yan, Richard C. Chao, Kyriakos P. Papadopoulos - Journal of Clinical Oncology 2022 被引用: 300

  16. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer

    著者: Charles M. Rudin, Martin Reck, Melissa L. Johnson, Fiona Blackhall, Christine L. Hann, James Chih‐Hsin Yang, Julie M. Bailis, Gwyn Bebb, Amanda Goldrick, John Umejiego, Luis Paz‐Ares - Journal of Hematology & Oncology 2023 被引用: 157

  17. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

    著者: David S. Hong, Brian A. Van Tine, Swethajit Biswas, Cheryl McAlpine, Melissa L. Johnson, Anthony J. Olszanski, Jeffrey Clarke, Dejka M. Araujo, George R. Blumenschein, Partow Kebriaei, Quan Lin, Alex J. Tipping, Joseph P. Sanderson, Ruoxi Wang, Trupti Trivedi, Thejo Annareddy, Jane P. F. Bai, Stavros Rafail, Amy Sun, Lilliam Fernandes, Jean‐Marc Navenot, Frederic D. Bushman, J.K. Everett, Derin F. Karadeniz, Robyn Broad, Martin Isabelle, Revashnee Naidoo, Natalie Bath, Gareth Betts, Zohar Wolchinsky, Dzmitry G. Batrakou, Erin Van Winkle, Erica Elefant, Armin Ghobadi, Amanda F. Cashen, Anne Grand’Maison, Philip L. McCarthy, Paula M. Fracasso, Elliot Norry, Dennis Williams, Mihaela Druta, David A. Liebner, Kunle Odunsi, Marcus O. Butler - Nature Medicine 2023 被引用: 194

  18. First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01

    著者: Toshio Shimizu, Jacob Sands, Kiyotaka Yoh, Alexander I. Spira, Edward B. Garon, Satoru Kitazono, Melissa L. Johnson, Funda Meric‐Bernstam, Anthony W. Tolcher, Noboru Yamamoto, Jon Greenberg, Yui Kawasaki, Hong Zebger‐Gong, Fumiaki Kobayashi, Penny Phillips, Aaron Lisberg, Rebecca S. Heist - Journal of Clinical Oncology 2023 被引用: 170

  19. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

    著者: Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer, Neal Ready, Daniel Morgensztern, Bonnie S. Glisson, Lauren A. Byers, Melissa L. Johnson, Howard A. Burris, Francisco Robert, Tae Hyung Han, Sheila Bheddah, Noah Theiss, Sky Watson, Deepan Mathur, Bharathi Vennapusa, Hany Zayed, Satwant Lally, Donald K. Strickland, Ramaswamy Govindan, Scott J. Dylla, Stanford L. Peng, David R. Spigel - The Lancet Oncology 2016 被引用: 553

  20. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial

    著者: Kim A. Reiss, Mathew G. Angelos, E. Claire Dees, Yuan Yuan, Naoto T. Ueno, Paula R. Pohlmann, Melissa L. Johnson, Joseph Chao, Olga Shestova, Jonathan S. Serody, Maggie Schmierer, Madison Kremp, Michael Ball, Rehman Qureshi, Benjamin H. Schott, Poonam Sonawane, Sabrina Ceeraz DeLong, Melissa Christiano, Ramona F. Swaby, Sascha Abramson, Ken Locke, Débora Barton, Eugene P. Kennedy, Saar Gill, Daniel J. Cushing, Michael Klichinsky, Thomas Condamine, Yara Abdou - Nature Medicine 2025 被引用: 192

  21. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer

    著者: Gregory J. Riely, Egbert F. Smit, Myung‐Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Anne S. Tsao, Melissa L. Johnson, Francesco Gelsomino, Raymond M. Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussain, Gregory A. Otterson, Ibiayi Dagogo‐Jack, Jonathan W. Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith D. Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E. Johnson - Journal of Clinical Oncology 2023 被引用: 114

  22. Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study

    著者: Melissa L. Johnson, Zanete Zvirbule, К. К. Лактионов, Åslaug Helland, Byoung Chul Cho, Vanesa Gutiérrez, Benoît Colinet, H. Léna, M. Wolf, Maya Gottfried, Isamu Okamoto, Cor van der Leest, Patricia Rich, Jen‐Yu Hung, Christina Appenzeller, Zhaowen Sun, David Maag, Yan Luo, Caroline Nickner, Alena Vajikova, Philip Komarnitsky, Jair Bar - Journal of Thoracic Oncology 2021 被引用: 156

  23. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results

    著者: Amy Rappaport, Chrisann Kyi, Monica Lane, Meghan G. Hart, Melissa L. Johnson, Brian S. Henick, Chih‐Yi Liao, Amit Mahipal, Ardaman Shergill, Alexander I. Spira, Jonathan W. Goldman, Ciaran D. Scallan, Desiree Schenk, Christine D. Palmer, Matthew J. Davis, Sonia Kounlavouth, Lindsey Kemp, Aaron Yang, Y. Li, Molly Likes, Annie Shen, Gregory R. Boucher, Milana Egorova, Robert L. Veres, J. Aaron Espinosa, Jason R. Jaroslavsky, Lauren D. Kraemer Tardif, Lindsey Acrebuche, Christopher Puccia, Leiliane Sousa, Rita Zhou, Kyounghwa Bae, J. Randolph Hecht, David P. Carbone, Benny Johnson, Andrew M. Allen, Andrew R. Ferguson, Karin Jooss - Nature Medicine 2024 被引用: 127

  24. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

    著者: Xiangnan Guan, Ruozhen Hu, Yoonha Choi, Shyam Srivats, Barzin Y. Nabet, John Silva, Lisa McGinnis, Robert L. Hendricks, Katherine Nutsch, Karl L. Banta, Ellen Duong, Alexis Dunkle, Patrick Chang, Chia-Jung Han, Stephanie Mittman, Nandini Molden, Pallavi Daggumati, Wendy Connolly, Melissa L. Johnson, Delvys Rodríguez‐Abreu, Byoung Chul Cho, Antoîne Italiano, Ignacio Gil‐Bazo, Enriqueta Felip, Ira Mellman, Sanjeev Mariathasan, David S. Shames, Raymond D. Meng, Eugene Y. Chiang, Robert J. Johnston, Namrata S. Patil - Nature 2024 被引用: 123